JNCCN 360

Editor:

Ursula A. Matulonis, MD

Advertisement

Advertisement

Recent News

Preclinical Study of TGF-β Inhibition in Ovarian Cancer

NCCN Collaborative Projects in Advanced Ovarian Cancer

Can Ovarian RADS MRI Identify Ovarian Cancer in Indeterminate Masses?

FDA Accepts sNDA for Niraparib in First-Line Maintenance Treatment of Ovarian Cancer

Fox Chase Researchers Receive Grant to Study High-Grade Serous Ovarian Cancer

CMS to Expand Coverage of Next-Generation Sequencing for Ovarian or Breast Cancer

FDA Grants Priority Review to Olaparib/Bevacizumab as Maintenance Therapy for Ovarian Cancer

Proteomic Analysis Identifies ADNP Gene as Mediator of Cell Proliferation in Ovarian Cancer

Protein Targeted in Ovarian Cancer Stem Cells

Are Calreticulin Levels Related to Ovarian Cancer Prognosis?

Identifying a Novel Pathway to Platinum Resistance in Ovarian Cancer

Novel Adenovirus Plus Chemotherapy for Platinum-Resistant Ovarian Cancer

Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

NCRI Conference: Early Testing for Levels of CA125 in Diagnosing Ovarian Cancer

Gift of $5M From Leonard A. Lauder to Advance Research in Ovarian Cancer

Does Trametinib Treatment Improve Outcomes in Rare Ovarian Cancer Subtype?

ESMO 2019: Activity of Cediranib Plus Olaparib in Platinum-Resistant Ovarian Cancer

Niraparib Approved by FDA for HRD-Positive Advanced Ovarian Cancer

ESMO 2019: ATR Inhibitor Plus Gemcitabine in High-Grade Serous Ovarian Cancer

ESMO 2019: Olaparib Plus Bevacizumab as Maintenance Therapy for Ovarian Cancer

Sections

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.